The drug is currently being evaluated in two fully recruited global Phase 3 studies for progressive and tophaceous gout, with results expected in 2026.
New unit boosts innovation in liposomal delivery technologies with 8,500 MT capacity and export-ready production
The congress aims at emphasizing on the most recent trends, advancements in the field of Obstetrics & Gynaecology
Aquavit will officially unveil the Dermatox and Microtox programs at the Annual American Academy of Dermatology, the world's largest dermatology conference scheduled from March 25-29, 2022, in Boston, MA
Subscribe To Our Newsletter & Stay Updated
